Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6552
    +0.0029 (+0.45%)
     

  • OIL

    83.79
    +0.22 (+0.26%)
     

  • GOLD

    2,359.60
    +17.10 (+0.73%)
     

  • Bitcoin AUD

    98,245.20
    +899.04 (+0.92%)
     

  • CMC Crypto 200

    1,389.49
    -7.05 (-0.50%)
     

  • AUD/EUR

    0.6095
    +0.0022 (+0.36%)
     

  • AUD/NZD

    1.0981
    +0.0024 (+0.22%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,109.15
    +30.29 (+0.37%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,053.91
    +136.63 (+0.76%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Here's Why You Should Retain NextGen Healthcare for Now

Zacks Equity Research

NextGen Healthcare, Inc. NXGN is well poised for growth backed by growing RCM (Revenue Cycle Management) and electronic health record (EHR) markets, and solid demand for other NextGen solutions. However, intense competition in the healthcare information technology market remains a concern.

Shares of NextGen Healthcare have gained 1.9%, compared with the industry’s growth of 11.3% in a year’s time. Meanwhile, the S&P 500 Index has rallied 18.4% in the same timeframe.

The company, with a market capitalization of $1.19 billion, is a developer and marketer of healthcare information systems. It anticipates earnings to improve 8% over the next five years. Moreover, it has beat estimates in the trailing four quarters by 3.5%, on average.

Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #3 (Hold).

What’s Deterring the Stock?

The company operates in the highly competitive healthcare information technology (HCIT) market, which in turn escalates pricing pressure.

Further, the company has been witnessing margin pressure for a considerable period of time and is likely to persist in the near term.

In fact, the gross margin in the fiscal second quarter was 51%, down 210 bps. Moreover, adjusted operating margin, as a percentage of revenues, was 56.2%, down 340 bps.



What’s Favoring the Stock?

Being a major player in the U.S. RCM space, the company continues to benefit from this market. The global RCM market is anticipated to reach $73.2 billion by 2026 at a CAGR of 12.0%.

Given the popularity of the RCM solution, the company intends to expand into dental and hospital markets. This, in turn, will boost the top line.

On the basis of the latest trend of EHR services in the U.S. MedTech space gaining prominence, the company is expected to benefit from the growing global EHR market.

According to Transparency Market Research, the global EHR market is estimated to reach $38.29 billion by 2025 at a CAGR of 5.7%. Further, reports indicate that MedTech companies with significant exposure to big data automated EHRs will excel with respect to operations and margins.

Apart from RCM, NextGen Healthcare will continue to benefit from strong demand for its other NextGen solutions that include Hospitals, EHR and practice management. NextGen’s Inpatient Clinicals, Lab and Patient Portal EHR solutions have also been gaining significant traction.

Strength in the company’s NextGen division is driving the company’s revenues. Moreover, recurring revenue stream and growing base of physicians, dentists and hospitals are other tailwinds.

Which Way Are Estimates Headed?

For fiscal 2020, the Zacks Consensus Estimate for revenues is pegged at $541.1 million, indicating an improvement of 2.2% from the prior-year period. The same for earnings stands at 86 cents per share, remaining flat from the year-ago reported figure.

Stocks to Consider

Some better-ranked stocks from the broader medical space are Conmed Corporation CNMD, West Pharmaceutical Services, Inc. WST and Edwards Lifesciences Corporation EW, each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Conmed has a long-term earnings growth rate of 17%.

West Pharmaceutical has a long-term earnings growth rate of 14%.

Edwards Lifesciences has a long-term earnings growth rate of 14.8%.

ADVERTISEMENT

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.

This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
 
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
 
CONMED Corporation (CNMD) : Free Stock Analysis Report
 
NEXTGEN HEALTHCARE, INC (NXGN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research